These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2970776)

  • 1. Coronary revascularization after intravenous tissue plasminogen activator for unstable angina pectoris: results of a randomized, double-blind, placebo-controlled trial.
    Topol EJ; Nicklas JM; Kander NH; Walton JA; Ellis SG; Gorman L; Pitt B
    Am J Cardiol; 1988 Sep; 62(7):368-71. PubMed ID: 2970776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo.
    Freeman MR; Langer A; Wilson RF; Morgan CD; Armstrong PW
    Circulation; 1992 Jan; 85(1):150-7. PubMed ID: 1728444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.
    Nicklas JM; Topol EJ; Kander N; O'Neill WW; Walton JA; Ellis SG; Gorman L; Pitt B
    J Am Coll Cardiol; 1989 Feb; 13(2):434-41. PubMed ID: 2492325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
    Williams DO; Topol EJ; Califf RM; Roberts R; Mancini GB; Joelson JM; Ellis SG; Kleiman NS
    Circulation; 1990 Aug; 82(2):376-83. PubMed ID: 2115407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
    Gold HK; Johns JA; Leinbach RC; Yasuda T; Grossbard E; Zusman R; Collen D
    Circulation; 1987 Jun; 75(6):1192-9. PubMed ID: 3105913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue plasminogen activator in refractory unstable angina. A randomized double-blind placebo-controlled trial in patients with refractory unstable angina and subsequent angioplasty.
    van den Brand M; van Zijl A; Geuskens R; de Feyter PJ; Serruys PW; Simoons ML
    Eur Heart J; 1991 Nov; 12(11):1208-14. PubMed ID: 1782951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction.
    Topol EJ; O'Neill WW; Langburd AB; Walton JA; Bourdillon PD; Bates ER; Grines CL; Schork AM; Kline E; Pitt B
    Circulation; 1987 Feb; 75(2):420-8. PubMed ID: 2948735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravenous thrombolysis by recombinant plasminogen activator (rt-PA) in unstable angina. A randomized multicenter study versus placebo].
    Charbonnier B; Bernadet P; Schiele F; Thery C; Baudouy M; Bauters C
    Arch Mal Coeur Vaiss; 1992 Oct; 85(10):1471-7. PubMed ID: 1297297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation (BARI).
    Whitlow PL; Dimas AP; Bashore TM; Califf RM; Bourassa MG; Chaitman BR; Rosen AD; Kip KE; Stadius ML; Alderman EL
    J Am Coll Cardiol; 1999 Nov; 34(6):1750-9. PubMed ID: 10577566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of percutaneous transluminal coronary angioplasty in the treatment of unstable angina. Report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Surgery Study Registries.
    Faxon DP; Detre KM; McCabe CH; Fisher L; Holmes DR; Cowley MJ; Bourassa MG; Van Raden M; Ryan TJ
    Am J Cardiol; 1984 Jun; 53(12):131C-135C. PubMed ID: 6233877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris.
    Ardissino D; Barberis P; De Servi S; Mussini A; Rolla A; Visani L; Specchia G
    Am J Cardiol; 1990 Oct; 66(12):910-4. PubMed ID: 2121016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indication for coronary revascularization for angina pectoris: correlation with prognosis of medically-treated patients].
    Yamasaki F; Hamashige N; Doi Y; Yonezawa Y; Kuzume O; Chikamori T; Odawara H; Takata J; Yamada M; Ozawa T
    J Cardiol; 1989 Dec; 19(4):1061-71. PubMed ID: 2486627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction. Observations from the TIMI IIIB Trial.
    Williams DO; Braunwald E; Thompson B; Sharaf BL; Buller CE; Knatterud GL
    Circulation; 1996 Dec; 94(11):2749-55. PubMed ID: 8941099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Percutaneous transluminal coronary angioplasty and aortocoronary bypass surgery in unstable angina pectoris and coronary multivessel disease].
    Karsch KR; Jaeck U; Mauser M; Voelker W; Huth C; Fenchel G; Seboldt H; Hoffmeister HE; Seipel L
    Dtsch Med Wochenschr; 1987 Jan; 113(2):49-52. PubMed ID: 2962848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of unstable angina in patients over 75 years old.
    Eggeling T; Hölz W; Osterhues HH; Pöhler E; Kochs M; Hombach V
    Coron Artery Dis; 1995 Nov; 6(11):891-6. PubMed ID: 8696534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute coronary syndromes: an update. II. Coronary revascularization and risk stratification].
    Auer J; Berent R; Maurer E; Mayr H; Weber T; Eber B
    Herz; 2001 Mar; 26(2):111-8. PubMed ID: 11349613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group.
    Arnold AE; Simoons ML; Van de Werf F; de Bono DP; Lubsen J; Tijssen JG; Serruys PW; Verstraete M
    Circulation; 1992 Jul; 86(1):111-20. PubMed ID: 1617763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.
    Califf RM; Topol EJ; George BS; Boswick JM; Lee KL; Stump D; Dillon J; Abbottsmith C; Candela RJ; Kereiakes DJ
    Circulation; 1988 May; 77(5):1090-9. PubMed ID: 2966016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery.
    Stephan WJ; O'Keefe JH; Piehler JM; McCallister BD; Dahiya RS; Shimshak TM; Ligon RW; Hartzler GO
    J Am Coll Cardiol; 1996 Nov; 28(5):1140-6. PubMed ID: 8890807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial).
    Bovill EG; Tracy RP; Knatterud GL; Stone PH; Nasmith J; Gore JM; Thompson BW; Tofler GH; Kleiman NS; Cannon C; Braunwald E
    Am J Cardiol; 1997 Feb; 79(4):391-6. PubMed ID: 9052337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.